About the Study
The purpose of the study is to collect blood from individuals who receive a licensed pneumococcal conjugate vaccine (PCV20, for Part 1 of the study and PCV21 for Part 2 of the study), also known as Prevnar 20 and Capvaxive, respectively, for protection against invasive pneumococcal disease caused by a bacteria called Streptococcus pneumoniae (or S. pneumoniae). Receiving either PCV20 or PCV21 vaccine can help the body fight the infection by making defenses (called antibodies) against S. pneumoniae.